STE · XBRL financial data

STERIS financial statements, every fiscal year

The same tables from 11 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STE's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue	3,108	4,585	4,958	5,139	5,460	5,936
Cost of goods and services sold	1,764	2,569	2,798	2,921	3,057	3,309
Gross profit	1,343	2,016	2,160	2,218	2,403	2,627
Research and development	66	88	102	104	108	113
Selling, general and administrative	731	1,503	1,299	1,252	1,334	1,408
Total operating expenses	795	1,591	1,892	1,382	1,536	1,525
Operating income (loss)	548	426	268	836	867	1,102
Interest expense	37	90	108	144	86	61
Other income (expense)	6	6	(3)	11	8	10
Income tax expense (benefit)	121	72	52	150	185	262
Net income (loss)	397	244	107	378	615	782
Earnings per share, basic USD per share	4.66	2.50	1.07	3.83	6.24	7.97
Earnings per share, diluted USD per share	4.63	2.48	1.07	3.81	6.20	7.93
Weighted average shares, basic millions of shares	85	98	100	99	99	98
Weighted average shares, diluted millions of shares	86	98	100	99	99	99

Fiscal years (STE's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	221	348	208	207	172	440
Accounts receivable	609	799	928	1,008	1,044	1,093
Inventory	315	575	695	675	581	632
Total current assets	1,212	1,879	2,011	2,869	2,001	2,395
Property and equipment, net	1,235	1,553	1,706	1,765	1,957	2,161
Right-of-use asset	150	188	192	173	156	155
Goodwill	3,026	4,404	3,879	4,071	4,096	4,195
Total assets	6,574	11,424	10,822	11,064	10,147	10,737
Accounts payable	157	226	280	252	281	339
Accrued liabilities	221	307	318	320	368	402
Total current liabilities	578	922	862	931	1,022	1,145
Long-term debt	1,651	2,945	3,019	3,120	1,919	1,813
Lease liability, non-current	130	155	160	146	125	120
Total liabilities	2,683	4,879	4,735	4,748	3,531	3,540
Retained earnings	1,939	1,999	1,912	2,088	2,475	3,016
Total stockholders' equity	3,881	6,532	6,077	6,302	6,603	7,184
Total liabilities and equity	6,574	11,424	10,822	11,064	10,147	10,737
Common shares outstanding (cover page) millions of shares	85	100	99	99	98	98

Fiscal years (STE's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	397	244	107	378	615	782
Stock-based compensation	26	58	39	57	57	62
Depreciation and amortization	219	553	553	565	476	487
Net cash from operating activities	690	685	757	973	1,148	1,341
Purchases of property and equipment	239	288	362	360	370	369
Net cash from investing activities	(1,154)	(667)	(383)	(887)	389	(513)
Share repurchases	15	56	309	12	211	236
Dividends paid	134	163	183	201	220	242
Repayments of long-term debt	35	—	—	—	—	—
Net cash from financing activities	346	116	(499)	(85)	(1,572)	(568)
Net change in cash	(99)	128	(140)	(1)	(35)	268

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Baxter International	1,975	2,976	558*	517.3M	—	Q3 FY26 10-QSep 30, 2026
West Pharmaceutical Services	464	875	190*	69.7M	—	Q3 FY26 10-QSep 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.